15 results about "Reduced appetite" patented technology

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

The present invention relates to a composition for reducing appetite and / or promoting weight loss, the composition comprising, in a first compartment, a first composition comprising a hydrophilic polymer selected from polysaccharides, their derivatives and mixtures, a crosslinking compound, a foaming agent and a foam stabilizing agent, and, in a second compartment, separate from the first compartment, a second composition comprising citric acid. The invention also relates to methods of administering the composition according to the invention to a human or animal subject.

A compound comprising a peptide chain which is an analogue of amylin, a terminal —NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The invention discloses an application of bifidobacterium animalis subsp. Lactis SS9 in preparation of a product for preventing and treating stress obesity. The bifidobacterium animalis subsp. Lactis SS9 obtained by screening can remarkably relieve obesity induced by combination of chronic pressure and high-fat diet, and the obesity is represented by slowing down weight increase, reducing appetite, improving blood fat, up-regulating GLP-1 and insulin secretion and effectively relieving anxiety-like and depression-like behaviors. Researches find that the strain can regulate the hypothalamic-pituitary-adrenal axis activation level, improve secretion imbalance of hormones such as CRH, ACTH and CORT, restore expression of appetite regulation factors such as NPY / AgRP / POMC of hypothalamic and relieve emotional eating behaviors. In addition, the strain can also reduce the systemic inflammation level, recover the diversity of intestinal flora and improve the proportion of beneficial bacteria. The invention provides the probiotics with multiple effects of regulating emotion, controlling body weight and improving metabolic disorder, and a new strategy is provided for preventing and treating stress-related obesity.

Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprising hexyalmine, for example, for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and / or memory in a human subject.

Disclosed herein are compositions comprising two or more of GLP-1R agonists. The description contained herein describes methods for promote weight loss, maintain healthy weight, prevent weight gain after ceasing use of the pharmaceutical products, reduce appetite cravings / boost satiety, and manage a healthy appetite by increasing GLP-1 levels in a subject. The compositions described herein may be formulated for oral administration, and in some embodiments, may further comprise enteric or pH-responsive coatings.

The present invention relates to a composition for reducing appetite and / or promoting weight loss, the composition comprising, in a first compartment, a hydrophilic polymer selected from polysaccharides, their derivatives and mixtures thereof, a crosslinking compound, a foaming agent, and a foam stabilizing agent, and, in a second compartment, separate from the first compartment, an acid selected from tartaric acid, succinic acid, ascorbic acid, and mixtures thereof. The invention also relates to methods of administering the composition according to the invention to a human or animal subject.

The present invention primarily relates to a combination agent for reducing appetite and / or for providing a feeling of satiety and / or for reducing energy intake and / or for reducing body weight. In addition, the present invention relates to a medical use of the combination agent, in particular for the treatment of overweight and obesity and for the prevention of cardiovascular disease, stroke, diabetes, and joint damage and wear of the spine, and to a non-therapeutic use of the combination agent. In particular, the focus of the present invention is on the use of the combination agent to provide a feeling of satiety and / or to reduce energy intake and / or to reduce body weight. Finally, the present invention relates to the use of the combination agent for the preparation of an orally consumable preparation or food ingredient and an orally consumable preparation or food ingredient prepared therefrom.

This invention discloses a strain of *Drugella*, its produced polysaccharide, and its applications. The *Drugella* G3 strain of this invention has the preservation number CCTCC NO: M 2024137. Its extracellular polysaccharide TDG3, as a TLR4 / DC-SIGN dual receptor agonist, exhibits a significant effect in reducing body weight. The extracellular polysaccharide TDG3 of this invention can significantly reduce appetite, decrease food intake, reduce body weight, and reduce adipose tissue content in mice. It can also alleviate or prevent obesity-induced hepatic steatosis. It is safe and non-toxic, suitable for preparing lipid-lowering and weight-loss drugs, and has good clinical application value and broad application prospects.

Compositions comprising fatty acid analogs are provided for treating conditions involving impaired cognition, movement disorders, chronic pain, depression, decreased appetite, addiction, seizure, and convulsion, and other conditions. Methods for the diagnosis and monitoring of impaired cognition, movement disorders, chronic pain, depression, decreased appetite, addiction, seizure, convulsion, and other conditions are also provided.

Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprising hexylamine, for example, for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and / or memory in a human subject.

Disclosed herein are compositions comprising two or more of GLP-1R agonists. The description contained herein describes methods for promote weight loss, maintain healthy weight, prevent weight gain after ceasing use of the pharmaceutical products, reduce appetite cravings / boost satiety, and manage a healthy appetite by increasing GLP-1 levels in a subject. The compositions described herein may be formulated for oral administration, and in some embodiments, may further comprise enteric or pH-responsive coatings.

The present invention relates to GDF15 analogs and methods for reducing body weight and / or reducing food intake. In particular, the present invention relates to fusion proteins comprising a half-life prolonging protein, a linker and a GDF15 protein, which fusion proteins are useful as GDF15 agonists. These GDF15 agonists are useful for treating obesity, reducing body weight, reducing food intake, or reducing appetite.

The purpose of the present invention is to provide a novel TRPA1 agonist. The present invention relates to a composition for activating TRPA1, comprising a mushroom extract or lanthionine. The composition can enhance appetite and food consumption and ameliorate decreased appetite.

Ascites and pleural effusion are common complications, and clinical interventions primarily based on symptomatic treatment often result in poor prognoses. Guided by the new theory of "inflammation-cancer" transformation, this invention discloses a traditional Chinese medicine composition for the prevention and treatment of ascites and pleural effusion, along with its preparation methods for internal and external use. The composition comprises the following medicinal materials in parts by weight: Codonopsis pilosula 3-20 parts, Atractylodes macrocephala 3-20 parts, Cinnamomum cassia 3-18 parts, Trichosanthes kirilowii 3-18 parts, Panax notoginseng 3-12 parts, Lobelia chinensis 3-15 parts, Polygonum bistorta 3-15 parts, Euphorbia helioscopia 3-15 parts, and Lepidium apetalum 3-15 parts. This traditional Chinese medicine composition possesses the effects of strengthening the body's resistance, removing blood stasis, detoxifying, eliminating dampness, promoting diuresis, and reducing swelling. It is effective in preventing and treating inflammatory and malignant ascites and pleural effusion, as well as the associated symptoms such as dyspnea, chest pain, cough, loss of appetite, abdominal pain, abdominal distension, fatigue, and night sweats. It can be prepared as a decoction, granules, pills, capsules, or powder. This invention helps promote the absorption and drainage of pleural and peritoneal effusions, reduce inflammation and fight cancer, adjust and restore the physiological functions of internal organs, and improve the quality of life of patients.